Tag: Upadacitinib
-
Upadacitinib Provides 1-Year Benefit for Pediatric IBD, Real-World Study Finds
Overview: Upadacitinib Shows Promising 1-Year Benefit in Pediatric IBD New findings from a real-world, single-center study suggest that upadacitinib (Rinvoq) can offer durable clinical benefits for children and adolescents with inflammatory bowel disease (IBD) over a 12-month period. The retrospective study followed 48 pediatric patients diagnosed with Crohn’s disease (CD) or ulcerative colitis (UC), exploring…
-
Upadacitinib Delivers One-Year Benefits for Pediatric IBD, Study Finds
Breakthrough Signals for Pediatric IBD Treatment In a retrospective, single-center study presented in Las Vegas, researchers reported that upadacitinib (Rinvoq) provided durable clinical benefit over a full year for children and adolescents with inflammatory bowel disease (IBD). The study, which evaluated 48 patients with Crohn’s disease (CD) or ulcerative colitis (UC), adds to a growing…
-
Upadacitinib Maintains 1-Year Benefit for Pediatric IBD: New Findings from a Single-Center Study
Overview New findings presented from a single-center retrospective study suggest that upadacitinib (Rinvoq), a JAK1 inhibitor, provides durable clinical benefit over a 12-month period for children and adolescents with inflammatory bowel disease (IBD). The study, conducted in a pediatric population with Crohn’s disease (CD) or ulcerative colitis (UC), underscores the potential of targeted therapy to…